ORIGINAL RESEARCH article
Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
This article is part of the Research TopicConfronting Antimicrobial Resistance: Trends, Interventions, and Socio-Economic ImpactsView all 3 articles
Mortality Risk Factors in Patients with Bloodstream Infections due to Multidrug-Resistant Gram-Negative Bacilli
Provisionally accepted- 1Division of Medicine, National Western Medical Center, Mexican Social Security Institute (IMSS), Guadalajara, Mexico
- 2Western Clinical Research Center, Zapopan, Mexico
- 3Health Sciences University Center, University of Guadalajara., Guadalajara, Mexico
- 4Divisions of Nephrology and Transplantation, National Western Medical Center, IMSS., Guadalajara, Mexico
- 5Divisions of Nephrology and Transplantation, National Western Medical Center, IMSS, Guadalajara, Mexico
- 6Epidemiological and Health Services Research Unit, National Western Medical Center, IMSS., Guadalajara, Mexico
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This study aimed to analyze risk factors for mortality in hospitalized patients with bloodstream infections caused by multidrug-resistant Gram-negative bacilli in a retrospective cohort (January–December 2022). Hospitalized patients with positive monomicrobial blood cultures for GNB (from central venous catheters and peripheral venipuncture) were included. Medical records and blood culture isolates were reviewed. The primary endpoint was all-cause mortality at ≤30 days. Risk factor analysis was performed using univariate models, survival curves (Cox regression), and an adjusted Cox proportional hazards model. A total of 126 patients with Gram-negative bacillus bloodstream infection were included; 36 died within ≤30 days, representing a mortality rate of 28.6%. Of these deaths, 32/36 (88.9%) were due to carbapenem-resistant bacilli. The most frequently isolated gram-negative bacilli were: Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. According to the univariate analysis, mortality was 13.2 times higher (95% CI 4.3–40.5; p = 0.000) in patients with carbapenem-resistant bacilli and 4.2 times higher (95% CI 1.8–9.6; p = 0.001) in those with carbapenem-resistant A. baumannii. The main factors associated with all-cause mortality within ≤30 days were: age ≥46 years, infection with carbapenem-resistant bacilli, ineffective empirical treatment, and septic shock. Having received ineffective empirical treatment was an independent predictor of mortality, with a hazard ratio (HR) of 10.2 (95% CI: 2.6-39.9; p = 0.001). Mortality due to bloodstream infection was related with a high frequency of patients with isolated infection by carbapenem-resistant gram-negative bacilli, mainly A. baumannii (CRAB).
Keywords: bloodstream infections, multidrug-resistant gram-negative bacilli, Mortality, Carbapenem-resistant Acinetobacter baumannii, ineffective empirical treatment
Received: 26 Aug 2025; Accepted: 26 Nov 2025.
Copyright: © 2025 Corona-Nakamura, Arias-Merino, Urbina-Rosas, Vázquez-Arias, Corona-Macías, González-Espinoza, Andrade Sierra, Nava-Zavala and Govea-Camacho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jorge Andrade Sierra
Luis Humberto Govea-Camacho
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
